Low complements and high titre of anti-Sm antibody as predictors of histopathologically proven silent lupus nephritis without abnormal urinalysis in patients with systemic lupus erythematosus

Rheumatology (United Kingdom)

Volumn 54, Issue 3, 2015, Pages 405-412

  Ishizaki, Jun ^a,b   Saito, Kazuyoshi ^a   Nawata, Masao ^a   Mizuno, Yasushi ^a   Tokunaga, Mikiko ^a   Sawamukai, Norifumi ^a   Tamura, Masahito ^a   Hirata, Shintaro ^a   Yamaoka, Kunihiro ^a   Hasegawa, Hitoshi ^b   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti Sm antibody; Complement; Silent lupus nephritis; systemic lupus erythematosus

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; RIBONUCLEOPROTEIN ANTIBODY; SERUM ALBUMIN; SM ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SILENT LUPUS NEPHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; URINALYSIS;

EID: 84941644454     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu343     Document Type: Article

References (36)

1. Cervera R, Khamashta MA, Font J et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine 1993;72:113-24.
2. Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999;10: 413-24.
3. Wallace DJ, Hahn B, Dubois EL. Dubois' Lupus Erythematosus. Philadelphia, PA, USA: Lippincott Williams & Wilkins, 2007.
4. Hollcraft RM, Dubois EL, Lundberg GD et al. Renal damage in systemic lupus erythematosus with normal renal function. J Rheumatol 1976;3:251-61.
5. Mahajan SK, Ordóñez NG, Feitelson PJ et al. Lupus nephropathy without clinical renal involvement. Medicine 1977;56:493-501.
6. Cavallo T, Cameron WR, Lapenas D. Immunopathology of early and clinically silent lupus nephropathy. Am J Pathol 1977;87:1-18.
7. Leehey DJ, Katz AI, Azaran AH, Aronson AJ, Spargo BH. Silent diffuse lupus nephritis: long-term follow-up. Am J Kidney Dis 1982;2:188-96.
8. O'Dell JR, Hays RC, Guggenheim SJ et al. Systemic lupus erythematosus without clinical renal abnormalities: renal biopsy findings and clinical course. Ann Rheum Dis 1985; 44:415-19.
9. Stamenkovic I, Favre H, Donath A et al. Renal biopsy in SLE irrespective of clinical findings: long-term follow-up. Clin Nephrol 1986;26:109-15.
10. Font J, Torras A, Cervera R et al. Silent renal disease in systemic lupus erythematosus. Clin Nephrol 1987;27: 283-88.
11. Zabaleta-Lanz ME, Muñoz LE, Tapanes FJ et al. Further description of early clinically silent lupus nephritis. Lupus 2006;15:845-51.
12. Wakasugi D, Gono T, Kawaguchi Y et al. Frequency of class III and IV nephritis in systemic lupus erythematosus without clinical renal involvement: an analysis of predictive measures. J Rheumatol 2012;39:79-85.
13. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40: 1725.
14. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1-150.
15. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 1992;38:1933-53.
16. Matsuo S, Imai E, Horio M et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982-92.
17. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15: 241-50.
18. Wada Y, Ito S, Ueno M et al. Renal outcome and predictors of clinical renal involvement in patients with silent lupus nephritis. Nephron Clin Pract 2004;98:105-11.
19. Will CL, Lührmann R. Spliceosomal UsnRNP biogenesis, structure and function. Curr Opin Cell Biol 2001;13: 290-301.
20. Zieve GW, Khusial PR. The anti-Sm immune response in autoimmunity and cell biology. Autoimmun Rev 2003;2: 235-40.
21. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
22. Clotet B, Guardia J, Pigrau C et al. Incidence and clinical significance of anti-ENA antibodies in systemic lupus erythematosus. Estimation by counter immuno electrophoresis. Scand J Rheumatol 1984;13:15-20.
23. Winn DM, Wolfe JF, Lindberg DA et al. Identification of a clinical subset of systemic lupus erythematosus by antibodies to the SM antigen. Arthritis Rheum 1979;22: 1334-37.
24. Barada FA Jr, Andrews BS, Davis JS 4th et al. Antibodies to Sm in patients with systemic lupus erythematosus. Correlation of Sm antibody titers with disease activity and other laboratory parameters. Arthritis Rheum 1981;24: 1236-44.
25. Janwityanuchit S, Verasertniyom O, Vanichapuntu M et al. Anti-Sm: its predictive value in systemic lupus erythematosus. Clin Rheumatol 1993;12:350-3.
26. Alba P, Bento L, Cuadrado MJ et al. Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann Rheum Dis 2003;62: 556-60.
27. Migliorini P, Baldini C, Rocchi V, Bombardieri S. Anti-Sm and anti-RNP antibodies. Autoimmunity 2005;38: 47-54.
28. Homma M, Mimori T, Takeda Y et al. Autoantibodies to the Sm antigen: immunological approach to clinical aspects of systemic lupus erythematosus. J Rheumatol Suppl 1987; 14:188-93.
29. Varela DC, Quintana G, Somers EC et al. Delayed lupus nephritis. Ann Rheum Dis 2008;67:1044-46.
30. Marto N, Bertolaccini ML, Calabuig E et al. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis 2005;64:444-8.
31. Gonzalez-Crespo MR, Lopez-Fernandez JI, Usera G et al. Outcome of silent lupus nephritis. Semin Arthritis Rheum 1996;26:468-76.
32. Schwartz N, Rubinstein T, Burkly LC et al. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther 2009;11:R143.
33. Rovin BH, Song H, Birmingham DJ et al. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 2005;16:467-73.
34. Rubinstein T, Pitashny M, Levine B et al. Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology 2010;49: 960-71.
35. Enghard P, Rieder C, Kopetschke K et al. Urinary CD4 T cells identify SLE patients with proliferative lupus nephritis and can be used to monitor treatment response. Ann Rheum Dis 2014;73:277-83.
36. DolffS, Abdulahad WH, Arends S et al. Urinary CD8+ T-cell counts discriminate between active and inactive lupus nephritis. Arthritis Res Ther 2013;15:R36.